AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04063969 — intervention group
Intervention type: OTHER
Intervention: Assessment of radiation safety behavior
Description: The rating tool contains 2 statements which cover 2 dimensions of the radiation safety behavior. Participants are asked to indicate on a scale of 1 (completely disagree) - 3 (neutral) - 5 (completely agree) whether they agree with each statement. A composite radiation safety behavior score is calculated by adding ratings on both items Minimum scale score 2 - Maximum scale score 10
Study NCT04063969 — intervention group
Intervention type: OTHER
Intervention: Assessment of radiation safety knowledge and motivation
Description: The rating tool contains 2 statements which cover the radiation safety knowledge and behavior. Participants are asked to indicate on a scale of 1 (completely disagree) - 3 (neutral) - 5 (completely agree) whether they agree with each statement.~Minimum item score 1 - maximum item score 5
Study NCT04063969 — intervention group
Intervention type: OTHER
Intervention: Data collection
Description: Collection of patient-related data points Demographic information: ASA-classification, BMI Procedure related information: Procedural time, approach, contrast usage case difficulty Radiation safety parameters: Air Kerma, DAP, fluoroscopy time
Study NCT04227093 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetazolamide
Description: Oral acetazolamide tablets of 250 mg taken twice daily.
Study NCT04227093 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets taken twice daily.
Study NCT03739281 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: PET/CT
Description: The included patients are imaged with PET/CT as part of normal clinical routine.
Study NCT00949234 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: tenofovir + emtricitabine, lopinavir/ritonavir
Description: The preferred regimen will be tenofovir + emtricitabine, provided as a fixed-dose combination tablet as Truvada®. Dosing is 1 tablet by mouth once daily. For participants with a creatinine clearance 30-49 mL/min, dosing of Truvada is 1 tablet by mouth every other day. For patients with creatinine clearance \<30 mL/min or on hemodialysis, Truvada should not be used. For intolerance to Truvada, Combivir (zidovudine 300mg/lamivudine 150mg)will be available to be taken as 1 PO BID. For highest-risk category exposures (receptive anal intercourse with a known or suspected HIV-positive source patient or in cases of suspected source drug resistance, see Schema, below) one of the following should be added to the above standard treatment, creating an expanded regimen:~Preferred: Lopinavir/ritonavir (200mg/50mg), 2 tablets orally twice daily or 4 tablets once daily
Study NCT02219529 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MCE
Study NCT00210314 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: high dose methotrexate
Study NCT00210314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: high dose methotrexate
Study NCT00210314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: high dose cytarabine
Study NCT00210314 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiotherapy
Study NCT00210314 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Study NCT00547703 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nortriptyline
Description: Nortriptyline 25mg capsule, orally administered, every night for 8 weeks
Study NCT00547703 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: An identical placebo capsule containing lactose, administered orally, every night for 8 weeks
Study NCT03999307 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low-Level Laser Therapy (LLLT)
Description: LLLT will be applied in this group
Study NCT03999307 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Flapless Corticopunture
Description: Small holes in the cortical bone will be achieved using 1-mm diameter round surgical Tungsten bur
Study NCT03999307 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: Typical orthodontic treatment with no LLLT or flapless corticopuncture
Study NCT00576667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rimonabant
Description: Tablet, oral administration
Study NCT00576667 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Rimonabant)
Description: Tablet, oral administration
Study NCT04606797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Description: Nicotine transdermal patches as per product monograph
Study NCT01953380 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: extended information
Study NCT02111473 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Testosterone
Description: Testosterone 250 mg injection per 3-4 weeks for 6 months
Study NCT00201266 — intervention group
Intervention type: PROCEDURE
Intervention: Screening
Description: Characterization tests including blood group typing, measures of lung function, measures of allergy, and collection of DNA.
Study NCT02642172 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ITF (Inulin/OFS 75/25)
Description: Participants will consume 16 g/day ITF
Study NCT01465646 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levothyroxine
Study NCT02642172 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will consume 16 g/day maltodextrin
Study NCT04042506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab 10 MG/ML Intravenous Solution [OPDIVO]
Description: 480mg IV every 4 weeks
Study NCT01465646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levothyroxine
Study NCT03298750 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resection of ovarian tissue and mechanical stimulation
Description: he women will undergo a surgical laparoscopy during which one of the two technique will ensue.~1. One of the ovaries will be scratched ( 2 mm depth) with a knife. Simultaneously, a piece of the ovary will be preserved for further histologic analysis and research in the laboratory.~2. A piece of one ovary will be resected (up to one third of the ovary's volume, without harming the other ovary.~The resected ovarian tissue will be transferred immediately to the laboratory where the cortex will be divided from the medulla and sliced to small pieces of 1-2 square millimeters.~These pieces will be transferred back to the operation room in order for them to be transplanted under the serosa layer of the remaining ovary.~Any bleeding would be stopped using a stiches or hemostatic mesh (diathermy will not be used).~Simultaneously, a piece of the ovary will be preserved for further histologic analysis and research in the laboratory.
Study NCT00122343 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ridaforolimus
Description: AP23573 will be administered intravenously (IV) at a fixed dose of 12.5 mg over 30 minutes once daily for 5 days (QDx5) every 2 weeks. A 4-week period comprised of 2 courses of AP23573 is defined as a cycle of treatment.
Study NCT03758911 — intervention group
Intervention type: OTHER
Intervention: Semi-structured Interview
Study NCT00949624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-868,596
Description: Oral tablet 60 mg BID continuous
Study NCT04042506 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy (SBRT)
Description: SBRT dose of 8-10 Gy x 3 fractions (at maximum 3 doses per week) delivered to 1 extracranial site between days 1-14 of Cycle 1.
Study NCT03648099 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Labor dance
Description: The dance group which involved pregnant women who performed the labor dance
Study NCT03648099 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music
Description: The music group involving pregnant women who were exposed to music.
Study NCT02219529 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard gastroscopy
Study NCT00166075 — intervention group
Intervention type: PROCEDURE
Intervention: Computer screen with community resource printout
Description: Patients participated in the screening process via a computer kiosk. Questions regarding IPV and mental health symptoms were asked using validated tools
Study NCT01846156 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MgSO4
Description: A randomized controlled study that compare three regimens for administration of MgSO4 used for the cases of severe pre-eclampsia that will be performed in the Obstetrics \& Gynecology Department, Kasr Al-Ainy Hospital, Cairo University
Study NCT02603016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLSE compound
Study NCT02603016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maitake mushroom extract compound
Study NCT01846156 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MgSO4
Description: A randomized controlled study that compare three regimens for administration of MgSO4 used for the cases of severe pre-eclampsia that will be performed in the Obstetrics \& Gynecology Department, Kasr Al-Ainy Hospital, Cairo University
Study NCT02603016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ginseng compound
Study NCT01869933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OC-10X
Study NCT00949624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Intravenous 75 mg/m2 every three weeks
Study NCT00949624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-868,596
Description: Oral tablet 100 mg BID continuous
Study NCT02079402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotonic crystalloids
Study NCT02079402 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isotonic crystalloids
Study NCT02941471 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Interferential Stimulation
Description: Transabdominal interferential electrcial stimulation
Study NCT01046175 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Air-stacking with a manual resuscitator
Description: Stacking air into the lungs up to maximal insufflation capacity (MIC)with a manual resuscitator
Study NCT01046175 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Air-stacking with ventilator
Description: Stacking air into the lungs to maximal insufflation capacity (MIC) with ventilator
Study NCT02941471 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TENS stimulation
Description: Transabdominal standard electrical stimulation
Study NCT03936036 — intervention group
Intervention type: DRUG
Intervention: Linagliptin
Description: Linagliptin dispensing claim is used as the exposure
Study NCT03936036 — intervention group
Intervention type: DRUG
Intervention: Sulfonylurea
Description: 2nd generation sulfonylurea dispensing claim is used as the reference
Study NCT03906799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OMT-28
Description: 1 capsule given daily orally from Visit 3 (Day 1) to Visit 8 (Day 99 ± 3 days).
Study NCT03906799 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 capsule given daily orally from Visit 3 (Day 1) to Visit 8 (Day 99 ± 3 days).
Study NCT01026753 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Refrigerator Magnet
Description: The refrigerator magnet contains a telephone number for a Provincial Health Contact Centre and a URL for a colorectal cancer Website that patients can access to learn more about colorectal cancer, screening and the fecal occult blood test. Patients can also have their questions answered.
Study NCT01602822 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 3 drug regimen: Tenofovir DF and Emtricitabine; Ritonavir-boosted Atazanavir
Description: TDF 300mg and FTC 200mg fixed-dose combination tablet (TDF/FTC) once daily, and atazanavir, one 300mg tablet and one 100 mg ritonavir given once daily
Study NCT01300715 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: lumbar medial branch radiofrequency neurotomy
Description: the classic tunnel vision technique versus the alternative technique
Study NCT04013906 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Rotational atherectomy
Description: Rotational atherectomy
Study NCT04028739 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: curmin
Description: curcumin 90mg/day cross-over
Study NCT02570945 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pharmacist-physician intervention to reduce high-risk medication use by elderly inpatients
Study NCT03208634 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic intervention
Description: One-month robotic intervention. Twelve sessions, three sessions a week, 40 minutes each. Twenty minutes of fully assisted reaching + 20 minutes of assisted Hand-to-Mouth
Study NCT01921504 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture treatment~1. Acupuncture rationale 1a) Style of acupuncture: body acupuncture (in accordance with meridian theory)~2. Needling details 2a) Number of needle insertions per subject per session: 9-19 2b) Acupoints: Basic points - Large Intestine(LI)4, Stomach(ST)36, Liver(LR)3, Spleen(SP)4, Conception Vessel(CV)12 Optional points - Gallbladder(GB)21, Small Intestine(SI)14, Pericardium(PC)6, External points of Hand and Neck(EX-HN)5, Stomach(ST)34 2c) Depth: 5 \~ 30mm 2d) Response sought: 'Deqi' 2e) Needle stimulation: Manipulation 2f) Retention time: 15 minutes 2g) Needle type: 25 X 30 mm, sterilized stainless steel needle, Dongbang Inc., Korea
Study NCT00668811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SU011248, Sutent
Description: Sutent 37.5 mg/day will be given orally after radioactive iodine therapy. Total time of Sutent drug administration will be 52 weeks, absent unacceptable toxicity or disease progression. Sutent is supplied as 12.5mg and 25 mg tablets. Patients are to swallow the tablets whole with approximately 250 ml (8 oz.) of water, fasting each morning. Patients will be given monthly calendars (patient diaries) to document the time when the Sutent pills are taken. At monthly visits, patients will bring back this record and the drug bottles.
Study NCT03052244 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS+VI
Description: 2mA will be delivered over 20min to M1 via neuroConn DC stimulator combined with video presenting walking legs.
Study NCT03052244 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS Sham+VI Sham
Description: 2mA will be delivered up to 30 sec to M1 via neuroConn DC stimulator combined with video presenting graphical illustration or nature movie for total duration of 20 min.
Study NCT05958797 — intervention group
Intervention type: DRUG
Intervention: Chloroquine
Description: Chloroquine will be administered according to body weight at a total dose of 25 mg base/kg over 3 days (10 mg base/kg on Day 0; 10 mg base/kg on Day 1 and 5 mg base/kg on Day 2). Correct drug dosage will be determined using the dosing chart (in accordance
Study NCT05958797 — intervention group
Intervention type: DRUG
Intervention: Primaquine
Description: For Pf patients, primaquine at 0.75 mg base/kg body weight single dose will be given on Day 3 for Pf patients; For Pv patients primaquine will be withheld for 28 days and will be given after Day 28 follow-up, at 0.25 mg base/kg per day for 14 days.
Study NCT02305212 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cogmed
Study NCT03235947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosfomycin disodium
Description: Fosfomycin disodium 4 g intravenously dissolved in 100 mL of normal saline 0.9% three times in the perioperative period of renal transplant surgery.
Study NCT03235947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimethoprim / Sulfamethoxazole
Description: Trimethoprim / Sulfamethoxazole (160/800 mg) orally every 24 hours during the study follow-up (7 weeks)
Study NCT03235947 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trimethoprim / Sulfamethoxazole
Description: Trimethoprim / Sulfamethoxazole (160/800 mg) orally every 24 hours during the study follow-up (7 weeks)
Study NCT03235947 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous placebo
Description: Normal saline 0.9% 100 mL intravenous administered three times in the perioperative period of the renal transplant, at the same times corresponding to disodium fosfomycin
Study NCT03813264 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine outcome measures (ROM)
Description: The proposed study consists of two complementary processes: the first is the routine collection of clinical data using ROM; The second process is MATRIX-based intervention that is expected to improve the course of treatment.
Study NCT03840707 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LIFEwithIBD
Description: LIFEwithIBD programme is a psychotherapeutic programme based on Acceptance, Mindfulness and Compassion for inflammatory bowel disease patients~Treatment as Usual (TAU): Standard personalized treatment of inflammatory bowel disease
Study NCT02885246 — intervention group
Intervention type: OTHER
Intervention: Data collection
Description: The ICGES database of Panama will be checked for all seasonal influenza A and/or B positive cases reported via influenza surveillance programs from 2010 to 2015.
Study NCT03399630 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Injection of Autologous Adipose Tissue
Description: Injection of Autologous Adipose Tissue to study the safety and efficacy of treating osteoarthritis
Study NCT03399630 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Injection of lactated ringers
Description: Injection of placebo lactated ringers to compare against the injection of autologous adipose tissue.
Study NCT00183326 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trauma-focused cognitive behavioral therapy (TF-CBT)
Description: TF-CBT is a psychotherapeutic intervention designed to help children, youth, and their parents overcome the negative effects of traumatic life events. It was developed by integrating cognitive and behavioral interventions with traditional child abuse therapies that focus on enhancement of interpersonal trust and empowerment. It targets PTSD symptoms, which often co-occur with depression and behavioral problems. TF-CBT also targets other issues experienced by those suffering a trauma including poor self-esteem, mood instability, and difficulty trusting others.
Study NCT00183326 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Child-centered supportive therapy (CCT)
Description: CCT demonstrates an empathic approach to healing. An environment consisting of empathy, unconditional positive regard and acceptance are key elements in this mode of therapy.
Study NCT04086914 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nerve Block
Description: This group will receive a nerve block consisting of 20mL of 5mg/mL ropivicanine and 0.1mL of 10mg'mL dexamethasone.
Study NCT00934219 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3-Acid Ethyl Esters
Description: LOVAZA, 1 g caps; High Dose Arm for 4 months, while on a standard therapy for hypertriglyceridemia (fibrates, +/-metformin). Standard Dose Arm for 3 months, while on a standard, unchanged therapy for hypertriglyceridemia (fibrates +/- metformin).
Study NCT00802152 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home monitoring
Description: The subject will take their blood pressure or glucose measurements 1-4 times per day, depending on patient condition. They will upload these measurements using the device to a secure website at least every other day. Data will be reviewed at least 2 times per week Monday through Friday by the clinic nursing staff. Data indicating problems, e.g., critical out of range values, will be communicated to the patient's primary care physician after review by the nurse. The physician will then determine what is needed for follow up action based on the patient's condition and data (e.g., telephone call to patient home, scheduling a clinic appointment, etc).
Study NCT04668066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07242813
Description: PF-07242813 given intravenously or subcutaneous
Study NCT01525615 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Respimat inhaler
Description: Respimat inhaler
Study NCT01525615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tiotropium+olodaterol (low dose)
Description: 2.5 µg tiotropium + 5 µg olodaterol
Study NCT01525615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tiotropium + olodaterol (high dose)
Description: 5 µg tiotropium + 5 µg olodaterol
Study NCT01525615 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Respimat inhaler
Description: Respimat inhaler
Study NCT01525615 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo to tiotropium+olodaterol
Description: comparator
Study NCT03831100 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BRIGHT
Description: The BRIGHT intervention consists of 5 weekly, 60-minute, tablet-based, one-one telehealth sessions with a licensed therapist. BRIGHT Therapist: A licensed clinical psychologist with extensive experience managing pyscho-oncologic concerns in patients with HNC will deliver BRIGHT.
Study NCT03831100 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Active Control
Description: AC consists of 5 weekly sessions of videos about HNC survivorship that are delivered using a telemedicine platform. Each AC session (Table 5) is a compilation of shorter videos featuring HNC survivors, caregivers, and oncologists discussing non-body image aspects of HNC survivorship.